首页> 美国卫生研究院文献>Journal of Cardiothoracic Surgery >Hybrid coronary revascularization versus coronary artery bypass grafting for multivessel coronary artery disease: systematic review and meta-analysis
【2h】

Hybrid coronary revascularization versus coronary artery bypass grafting for multivessel coronary artery disease: systematic review and meta-analysis

机译:混合冠状动脉血运重建与冠状动脉搭桥术治疗多支冠状动脉疾病:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe concept of hybrid coronary revascularization (HCR) combines the left internal mammary artery (LIMA)–left anterior descending (LAD) graft and percutaneous coronary intervention (PCI) to non-LAD vessels. Multiple comparative studies have evaluated the safety and feasibility of HCR and coronary artery bypass grafting (CABG) for multivessel coronary artery disease (MCAD). However, the sample size of each study was small, and evidences based on single-institutional experience. The purpose of this meta-analysis was to compare the short-term outcomes of HCR with those of CABG for MCAD.
机译:背景技术混合冠状动脉血运重建术(HCR)的概念是将左乳内动脉(LIMA)-左前降支(LAD)移植物和经皮冠状动脉介入治疗(PCI)结合到非LAD血管上。多项比较研究评估了HCR和冠状动脉搭桥术(CABG)对多支冠状动脉疾病(MCAD)的安全性和可行性。但是,每项研究的样本量都很小,并且证据来自单一机构的经验。这项荟萃分析的目的是比较HCR和CABG对MCAD的短期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号